Randomized trial of low nicotine cigarettes plus electronic cigarettes in smokers with a mental health condition

对有心理健康状况的吸烟者进行低尼古丁香烟加电子烟的随机试验

基本信息

项目摘要

Project Summary/Abstract The long term goal of this project is to determine the likely health effects in Smokers with Mental Health Conditions (SMHC) of a rule requiring very low nicotine content in cigarettes, in conjunction with availability of nicotine-containing electronic cigarettes (ecigs). This will be tested in a rigorous randomized controlled trial design. We plan to use a comprehensive set of measures of proven validity and reproducibility, including toxicant exposure (urinary NNAL, exhaled CO), addiction (FTND) and mental health (Kessler K6) to assess these effects. This is a prospective parallel-group randomized double-blind, 2-by-2 controlled trial in which 240 current smokers with mental health conditions will be randomized to one of 4 groups: 1) normal nicotine content cigarettes (11mg nicotine content per cigarette, NNCs) and 15mg/mL nicotine ecigs; 2) NNCs and zero mg/mL nicotine ecigs; 3) Very low nicotine content cigarettes (0.2mg nicotine/cigarette, VLNCs) and 15mg/mL nicotine ecigs 4) VLNCs and zero mg/mL nicotine ecigs. They will be followed for 16 weeks on study products and then another 4 weeks thereafter. Participants will first complete a preliminary phone eligibility assessment and an in-person screening. Next, an in person assessment visit will be scheduled to complete informed consent and determine eligibility. After 1 week of smoking their own brand of cigarettes, participants will receive 2 weeks of the NNC cigarettes and be asked to keep a cigarette log. Eligible participants will be randomly assigned to one of the four groups using a computer algorithm developed by study statisticians and overseen by the Penn State Investigational Drug Pharmacy. The Pharmacy will also prepare blinded cigarettes and e-cig devices. All study products will be relabeled to ensure participants and staff are blinded to the nicotine content. At the end of the 16-week randomization phase, participants will come to their last visit, receive encouragement to quit all tobacco products and be given resources in the community where they can receive smoking cessation counseling. Participants will be asked to provide information about their intentions for ongoing tobacco product use or cessation and will be followed up 4 weeks later to assess these outcomes. Those claiming to be no longer using combustible tobacco products will be visited to verify with a measure of exhaled CO.
项目摘要/摘要 该项目的长期目标是确定有心理健康问题的吸烟者可能对健康造成的影响 要求香烟中尼古丁含量极低的规则的条件(SMHC),以及 含尼古丁电子烟(Ecigs)。这将在一项严格的随机对照试验中进行测试 设计。我们计划使用一套全面的经过验证的有效性和可重复性的衡量标准,包括 毒物暴露(尿NNAL,呼出的CO),成瘾(FTND)和精神健康(Kessler K6)评估 这些影响。 这是一项前瞻性、平行组、随机、双盲、2x2对照试验,其中240 目前有心理健康问题的吸烟者将被随机分为4组:1)正常尼古丁 含量香烟(每支香烟11毫克尼古丁含量,NNC)和15毫克/毫升尼古丁;2)NNC和0 3)尼古丁含量极低的香烟(0.2 mg尼古丁/支,VLNC)和15 mg/mL 尼古丁提取物4)VLNCs和0 mg/mL尼古丁提取物。他们将对研究产品进行为期16周的跟踪调查 然后再过4周。参与者将首先完成初步的电话资格评估 还有一场面对面的放映。接下来,将安排一次面对面的评估访问,以完成通知 同意并确定资格。在吸食自己品牌的香烟一周后,参与者将 接受两周的NNC香烟,并被要求保留香烟日志。 合格的参与者将使用计算机算法随机分配到四组中的一组 由研究统计学家开发,由宾夕法尼亚州立大学调查药物药房监督。这个 药房还将准备盲烟和电子烟设备。所有研究产品将重新贴上标签,以确保 参与者和工作人员对尼古丁含量视而不见。在为期16周的随机阶段结束时, 参与者将来到他们的最后一次访问,获得戒烟的鼓励,并获得 社区资源,在那里他们可以接受戒烟咨询。参与者将被问及 提供有关他们持续使用烟草产品或戒烟的意图的信息,并将被遵守 4周后对这些结果进行评估。声称不再使用可燃烟草的人 将访问产品以验证呼出的CO的量度。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JONATHAN FOULDS其他文献

JONATHAN FOULDS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JONATHAN FOULDS', 18)}}的其他基金

Penn State TCORS: Tobacco Product Composition Effects on Toxicity and Addiction
宾夕法尼亚州立大学 TCORS:烟草产品成分对毒性和成瘾性的影响
  • 批准号:
    10665895
  • 财政年份:
    2023
  • 资助金额:
    $ 44.85万
  • 项目类别:
Project 3: Randomized Placebo-controlled Trial of Nicotine Pouches in Smokers
项目 3:吸烟者尼古丁袋的随机安慰剂对照试验
  • 批准号:
    10665898
  • 财政年份:
    2023
  • 资助金额:
    $ 44.85万
  • 项目类别:
Does Switching to Nicotine-containing Electronic Cigarettes Reduce Health Risk Markers?
改用含尼古丁的电子烟会减少健康风险标志吗?
  • 批准号:
    9752508
  • 财政年份:
    2018
  • 资助金额:
    $ 44.85万
  • 项目类别:
Does Switching to Nicotine-containing Electronic Cigarettes Reduce Health Risk Markers?
改用含尼古丁的电子烟会减少健康风险标志吗?
  • 批准号:
    10294089
  • 财政年份:
    2018
  • 资助金额:
    $ 44.85万
  • 项目类别:
Random nicotine delivery: A novel intervention for smokers
随机尼古丁输送:针对吸烟者的新型干预措施
  • 批准号:
    8809791
  • 财政年份:
    2014
  • 资助金额:
    $ 44.85万
  • 项目类别:
Random nicotine delivery: A novel intervention for smokers
随机尼古丁输送:针对吸烟者的新型干预措施
  • 批准号:
    8925844
  • 财政年份:
    2014
  • 资助金额:
    $ 44.85万
  • 项目类别:
Project 2: Reduced Nicotine Cigarettes in Smokers with Mood and Anxiety p248-288
项目 2:减少情绪和焦虑吸烟者的尼古丁香烟 p248-288
  • 批准号:
    8737840
  • 财政年份:
    2014
  • 资助金额:
    $ 44.85万
  • 项目类别:
Pennsylvania State University Tobacco Center of Regulatory Science (TCORS)
宾夕法尼亚州立大学烟草监管科学中心 (TCORS)
  • 批准号:
    8919320
  • 财政年份:
    2013
  • 资助金额:
    $ 44.85万
  • 项目类别:
Pennsylvania State University Tobacco Center of Regulatory Science (TCORS)
宾夕法尼亚州立大学烟草监管科学中心 (TCORS)
  • 批准号:
    8582174
  • 财政年份:
    2013
  • 资助金额:
    $ 44.85万
  • 项目类别:
Project 2: Reduced Nicotine Cigarettes in Smokers with Mood and Anxiety p248-288
项目 2:减少情绪和焦虑吸烟者的尼古丁香烟 p248-288
  • 批准号:
    8594387
  • 财政年份:
    2013
  • 资助金额:
    $ 44.85万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 44.85万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.85万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 44.85万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.85万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 44.85万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.85万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 44.85万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 44.85万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 44.85万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.85万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了